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7. ABSTRAK 
Objektif: 
Untuk menentukan keberkesanan suntikan intravitreal ranibizumab ke atas arnab 
yang diransang  ketumbuhan retinoblastoma, dan untuk menentukan kebarangkalian 
kesan sampingan ubat berkenaan. 
 
Tatacara: 
Ketumbuhan retinoblastoma telah dihidupkan ke dalam mata 6 ekor arnab New 
Zealand White rabbit dengan kaedah suntikan sel asas WERI-Rb ke dalam kawasan 
bawah retina mata kanan arnab tersebut. Selepas enam minggu, kumpulan A (n=3) 
telah  diberi suntikan intravitreal ranibizumab (0.5mg) dan kumpulan B (n=3) 
sebagai kumpulan kawalan. Pemeriksaan klinikal asas dan secara berkala telah 
dijalankan pada hari pertama, ketiga, keenam, kedua belas, kelima belas, kelapan 
belas dan  kedua puluh satu. Mata kanan telah dienukleasi pada hari kedua puluh 
satu dan dihantar ke makmal untuk ujian histopatologi. 
 
Keputusan: 
Ketumbuhan tisu  telah dapat dikesan secara klinikal tumbuh pada bahagian bawah 
retina atau retina dan juga kawasan gel vitreous bermula satu minggu selepas 
suntikan sel ketumbuhan.  Ketumbuhan yang dikesan tumbuh secara perlahan tanpa  
 xii 
 
tanda-tanda menyusut dengan sendiri. Selepas diberi suntikan intravitreal 
ranibizumab (0.5mg), terdapat kesan menyusut yang sedikit sementara ketumbuhan 
pada kumpulan kawalan terus bertumbuh secara perlahan. Ujian histopatologi 
mengesahkan ketumbuhan tersebut adalah sangat menyerupai sel retinoblastoma 
jenis tidak membahagi pada manusia. Ketumbuhan itu juga didapati lebih besar 
saiznya pada kumpulan kawalan berbanding kumpulan yang diberi rawatan. Walau 
bagaimanapun, kumpulan A yang diberi rawatan juga ada menunjukkan kesan 
pertumbuhan ‘hyperplasia’ pada retina. Tiada kesan sampingan merbahaya akibat 
suntikan ranibizumab melainkan kenaikan tekanan mata yang berlaku sejurus selepas 
suntikan. Kenaikan tekanan mata itu telah  menurun seperti biasa setelah 
‘paracentesis’ dijalankan. 
 
Kesimpulan 
Suntikan intravitreal ranibizumab (0.5mg) menyebabkan penyusutan ketumbuhan 
pada mata arnab. Walau bagaimanapun, keputusan ini didapati tidak signifikan 
secara statistik. Terdapat peningkatan tekanan mata sejurus selepas suntikan 
intravitreal ranibizumab yang menurun seperti biasa setelah ‘paracentesis’ 
dijalankan. Oleh itu, rawatan ini didapati selamat. 
 
. 
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8. ABSTRACT 
Objective:  
To determine the efficacy of intravitreal ranibizumab injection in rabbit induced with 
retinoblastoma and to determine the potential side effect of intravitreal ranibizumab 
injection in rabbit induced with retinoblastoma 
 
Methodology: 
Retinoblastoma was induced in 6 New Zealand White rabbit by subretinal injection 
of cultured WERI-Rb cell line into the right eye. After six week, Group A (n=3) was 
given intravitreal ranibizumab injection (0.5mg) and Group B (n=3) as control 
group. Baseline and serial clinical examination was performed at day 1, 3, 6, 12, 15, 
18, 21. The right eyes were enucleated on day 21 and sent for histopathological 
examination. 
 
Results: 
All rabbits developed intraocular tumour in the subretinal/retinal and vitreous cavity 
detectable via fundus examination started after one week post tumour inoculation. 
The tumour grew slowly without evidence of spontaneous regression. After 
intravitreal ranibizumab injection in Group A (treated group), there was slight 
regression of the tumour detected clinically while the tumour in the group B (control 
group) continued to grow slowly. Histopathological finding confirmed presence of 
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tumour that closely resembled features of poorly differentiated human 
retinoblastoma cells. The tumour in the control group was larger compare to the 
treated group. The treated group however also developed focal area of retinal 
hyperplasia. There was no significant side effect of ranibizumab injection except 
temporary high intraocular pressure immediate post injection which relieved after 
paracentesis. 
 
Conclusion: 
Intravitreal injection ranibizumab (0.5mg) caused regression of tumour in this 
xenograft rabbit model clinically. However, the result was not statistically 
significant. There was temporary increase in intraocular pressure immediately post 
injection which relieve with paracentesis. Therefore, it was considered as a safe 
therapy. 
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Chapter 1 
____________________________________________________________________ 
Introduction 
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1.1  Overview of retinoblastoma       
 
Retinoblastoma is the most common primary intraocular tumour in childhood with 
an incidence of 1 in 15,000 to 20,000 live births (Bishop & Madsen, 1975). It 
represents approximately 4% of paediatric malignancies (Shields & Shields, 2004). 
The first enucleation for retinoblastoma was advocated by James Wadrop in 1809 
(Abramson, 2005).  Before the role of enucleation in the management of 
retinoblastoma was known, most cases of retinoblastoma proved fatal (Shields & 
Shields, 2004). As more patients survived and had their offspring, more evidence 
arose suggesting the hereditary nature of retinoblastoma (Abramson, 2005). There is 
no predilection in gender, race and socioeconomic status. However, patient from 
lower socioeconomic background has more advanced forms of disease at initial 
diagnosis and the median age at diagnosis tend to be substantially higher due to late 
presentation (Erwenne & Franco, 1989). With current chemotherapy and focal 
treatment modalities, survival in the United States and other developed countries has 
now climbed to almost 100% with children maintaining functional vision but in 
other continents such as Africa, survival rates drop significantly (Houston et al., 
2012).  
 
Retinoblastoma is generally classified into familial or sporadic, bilateral or 
unilateral, and heritable or non-heritable (Shield & Shields, 2002). The tumour is 
commonly unilateral (60%) with median age at presentation under 12 months in  
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heritable cases, and closer to 24 months in sporadic cases (Abramson & Servodidio, 
1992). Retinoblastoma is initiated by mutations in both alleles of the RB1 tumour 
suppressor gene located on the long arm of chromosome 13 (13q14.2)(Sachdeva & 
Brien, 2012). Mutation of Rb1 allele results in defective formation of pRB protein 
leading to impaired cell cycle and uncontrolled cell proliferation (Bunin et al., 1989). 
Knudson (1971) proposed the ‘two hit’ hypothesis that the development of 
retinoblastoma is due to two mutational events.  About 40% of retinoblastoma cases 
are heritable, with RB1 mutations occur ring in the germline while 60% are non-
heritable (Knudson, 1971;  Bunin et al., 1989). In heritable cases, the initial mutation 
of RB1 allele may be known to be present within the family (familial retinoblastoma, 
25% of heritable cases) or may have occurred de novo in the parental gametes 
(sporadic heritable, 75% of heritable cases) (Sachdeva & Brien, 2012 ; Bunin et al., 
1989). Subsequent mutation of the second allele occurs within the developing retina, 
resulting in the development of intraocular tumours. In non-heritable cases, both 
RB1 mutations occur locally within the affected retina ( Knudson, 1971; Bunin et al. 
1989; Mairal et al., 2000). 
 
The clinical features of retinoblastoma vary with the stage of the disease at the time 
of the diagnosis. The earlier and the most frequent clinical manifestations of 
retinoblastoma are leukocoria and strabismus (Shields & Shields, 2004 ; Dimaras et 
al., 2012). Leukocoria is initially inconstant and visible only at certain angles and 
(Aerts et al., 2006). Strabismus, when present, becomes rapidly constant due to  
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impairment of the vision (Aerts et al. 2006). Other signs include rubeosis iridis, 
hypopyon, hyphaema, buphthalmos and orbital cellulitis (Aerts et al., 2006; Dimaras 
et al., 2 012). Some children with retinoblastoma may have no symptoms. Screening 
cases with positive family history or dysmorphic syndrome with a 13q14 deletion 
may lead to diagnosis of retinoblastoma (Baud et al., 1999). 
 
Diagnosis establishment in a child with suspected retinoblastoma is accomplished by 
thorough history and physical evaluation including external ocular examination, slit 
lamp biomicroscopy, and binocular indirect ophthalmoscopy with   indentation. The 
diagnosis is established by the classic appearance of the retinal tumours by an 
experienced examiner. In general, retinoblastoma appears as a whitish retinal mass 
that may be solitary or multifocal (Houston et al., 2012).  
 
At early clinical stage, a small retinoblastoma less than 2 mm in basal dimension, 
appears as a subtle, slightly translucent lesion in the sensory retina (Shield & Shield, 
1992). Larger tumours lead to dilated retinal blood vessels and may show foci of 
chalk-like calcification that resemble cottage cheese. Retinoblastoma of any size can 
produce leukocoria particularly larger tumour. The white pupillary reflex is a result 
of reflection of light from the white mass in the retrolental area (Shields & Shields, 
2004).  
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Ancillary diagnostic studies such as fundus fluorescein angiography and 
ultrasonography can be helpful in confirming the diagnosis of retinoblastoma 
(Shields & Shields, 2004). Fluorescein angiography shows early vascularity and late 
hyperfluorescence of the tumour. Ultrasonography and computed tomography can 
demonstrate the intraocular tumour and possibly the calcification area. 
Approximately 5% to 10% of retinoblastomas show no intrinsic calcification. 
Magnetic resonance imaging does not usually detect calcium but may be of value in 
the assessment of the optic nerve, orbit, and brain. Optic coherence tomography has 
been found useful in the detection of cystic retinoblastoma that might show less 
dramatic response to chemotherapy, and it is also helpful in the follow-up of patients 
to assess macular anatomy. 
 
Retinoblastoma is a highly malignant intraocular tumour of childhood that requires 
accurate diagnosis and prompt treatment. When left untreated, it is almost always 
fatal. The most important objective in the management of retinoblastoma is to save 
life (Shield & Shield, 2004). Salvation of the globe and vision are the secondary and 
tertiary goals respectively. Enucleation is the most commonly employed surgical 
modality for advanced retinoblastoma, especially when there is a concern of the 
spread to the optic nerve, choroid, or orbital cavity.  
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Two classifications are currently used for prognosis or survival of retinoblastoma. 
The Reese Ellsworth Classification was originally developed to predict globe salvage 
after external beam radiotherapy (Table 1) (Ellsworth, 1969). The International 
Classification of Retinoblastoma (ICRB) is the new classification system which 
simplifies the grouping scheme and allows a more practical approach in judging 
results of chemoreduction (Shield et al., 2004). This classification is based on 
tumour size, location, and associated seeding (Table 2). Shield & Shield (2006) 
suggested that this classification can reliably predict chemoreduction outcome, as 
success was achieved in 100% of group A, 93% of group B, 90% of group C, and 
47% of group D cases. In advanced retinoblastoma, TNM classification is used for 
the staging. 
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Table 1.1: Reese-Ellsworth Classification for Conservative Treatment of 
Retinoblastoma 
      *Refers to chances of salvaging the affected eye and not systemic prognosis. 
 
 
 
 
 
 
Group  Likelihood of Globe Salvage Features 
I Very favourable  a.  Solitary tumour, <4 disc 
diameters, at or behind equator 
 
b.  Multiple tumours, none <4 disc 
diameters, all at or behind equator 
 
II Favourable a.  Solitary tumour, 4-10 disc 
diameters, at or behind equator 
 
b.  Multiple tumours, 4-10 disc 
diameters, behind 
 
III  Doubtful a.  Any lesion anterior to equator 
 
b.  Solitary tumours <10 disc  
diameters behind equator 
 
IV  Unfavourable  a.  Multiple tumours, some >10 
disc diameters 
b.  Any lesion extending 
anteriorly to ora serrata 
 
V Very unfavourable a.  Massive tumours involving 
more than half of retina 
 
b.  Vitreous seeding 
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Table 1.2:  International Classification of Retinoblastoma (ICRB) 
Group  Features 
A Small tumour: ≤ 3 mm 
 
B Large tumour: >3 mm  
Macular: ≤ 3 mm to foveola 
Juxtapapillary: ≤ 3 mm to disc 
Subretinal fluid: ≤  3 mm from the tumour margin 
 
C 
    C1 
    C2 
    C3 
Focal seeds 
Subretinal seeds: ≤ 3mm from tumour 
Vitreous seeds: ≤ 3 mm from tumour 
Both subretinal and vitreous seeds: ≤ 3 mm from tumour 
 
D 
     D1 
     D2 
     D3 
Diffused seeds 
 
Subretinal seeds: >3 mm 
Vitreous seeds: >3 mm 
Both subretinal and vitreous seeds: >3 mm 
 
E Extensive retinoblastoma occupying more than 50% or  
neovascular glaucoma or  
opaque media from hemorrhage in anterior chamber, 
vitreous or subretinal space 
Invasion of postlaminar optic nerve, > 2mm of choroid, 
sclera, orbit, or anterior chamber 
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1.2 Treatment modalities of retinoblastoma 
 
The management of retinoblastoma has evolved tremendously for the past century. 
The success in managing retinoblastoma is attributable to general developments in 
medicine, along with the specialised development of ophthalmic techniques such as 
laser photocoagulation and cryosurgery. In 1921 the first eye with retinoblastoma 
was salvaged and in 1926 the first case was reported of successful treatment of 
retinoblastoma with retention of sight (Abramson, 2005). External beam 
radiotherapy is a method of delivering whole eye irradiation to treat advanced 
retinoblastoma, particularly when there is diffuse vitreous seeding (Shields & 
Shields 2004). Various treatment plans have been employed including the whole eye 
technique and lens-sparing technique. Recurrence of retinoblastoma after external 
beam radiotherapy continues to be a problem that can develop within the first 1 to 4 
years post treatment. Tumour recurrence has also been found to be related to the 
stage of the disease and largest tumour size at the time of treatment (Shields & 
Shields 2004). 
 
The most current method for retinoblastoma treatment is chemoreduction followed 
by focal consolidation therapy (Shield & Shield, 2008). It has largely replaced the 
external-beam radiotherapy (ERBT) as the treatment of choice for bilateral 
retinoblastoma. EBRT which has been used for treating advanced retinoblastoma 
currently has lost its favour due to increased risk of secondary tumour and also effect 
of radiation causing damage to surrounding intraocular structure (Weiss et al., 1994). 
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The risk of secondary malignancies is greater than 50% by the age of fifty years if 
the retinoblastoma is treated with EBRT (Wong et. al., 1997).     
 
The International Classification of Retinoblastoma (ICRB) is very useful in guiding 
the clinician to choose the most appropriate treatment methods and assist the 
predication of the success of chemoreduction and focal treatment. In general, eyes 
classified as group A is managed by primary focal therapy such as cryotherapy, laser 
photocoagulation or transpuppillary thermotherapy (TTT ). Group B is managed by 
six cycles of chemotherapy, especially if only two drugs are used followed by focal 
consolidation while Group C with six cycles of chemotherapy plus focal 
consolidation therapy. By using the ICRB, the bilateral cases of group D or E are 
managed by chemoreduction, thermotherapy or low dose of external beam 
radiotherapy, but group E often require enucleation. 
 
Chemoreduction involves intravenous chemotherapy to reduce the tumour size, 
followed by focal consolidation to permanently devitalize each retinoblastoma 
(Shields et al., 2004). The benefits of chemoreduction are not only tumour control 
within the eye, but may also prevent or delay the onset associated pinealoblastoma 
and other intracranial neuroblastic malignancies (trilateral retinoblastoma). 
Chemoreduction has been most successful for eyes with tumour confined to the 
retina and least successful for eyes with additional vitreous and subretinal seeds and 
those eyes with subretinal fluid at initial examination (Shields et al., 2002). Eyes that 
failed chemoreduction is generally treated with external beam radiotherapy or 
enucleation (Shields et al., 2002). 
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The focal treatment modalities include laser photocoagulation, cryotherapy, 
transpupillary thermotherapy (TTT), chemothermotherapy and custom design plaque 
radiotherapy. These focal therapies are employed for small tumours, especially those 
that have been reduced by chemoreduction (Shields & Shields, 2004). Laser 
photocoagulation is performed using the indirect ophthalmoscopic argon or green 
diode laser with two rows of photocoagulation surrounding the tumour base and 
avoiding direct treatment to the tumour as it could lead to vitreous seeding. Laser 
photocoagulation is usually employed for small retinoblastomas posterior to the 
equator of the eye. In this era of chemoreduction, laser photocoagulation is rarely 
employed as its success depends on vascular coagulation and tumour ischaemia, 
whereas the opposite applies to chemoreduction. Thus, it is not employed in eyes 
receiving chemoreduction.  
 
Cryotherapy was introduced by Harvey Lincoff et al. in the 1960s and has proven to 
be an important adjunct in the treatment of peripheral, small retinoblastomas. 
Cryotherapy remains an important method for tumour consolidation following 
chemoreduction. The therapy is useful in the treatment of equatorial and peripheral 
small retinoblastomas. It is a critical modality for management of recurrent 
subretinal seeds near the ora serrata (Shields & Shields, 2004). 
 
Enucleation is still an important management in advanced disease with no hope for 
useful vision in the affected eye or if there is a concern of invasion of the tumour 
into the optic nerve, choroid, or orbit (Shields & Shields 2004). Eyes with secondary 
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glaucoma, pars plana seeding, or anterior chamber invasion are also generally best 
managed with enucleation 
 
1.3 Animal model of retinoblastoma  
 
Animal model of retinoblastoma is important particularly to study the efficacy of 
new therapies. It has been established previously mostly in murine models which 
includes the transgenic murine model and knockout mice. The majority of the animal 
models are xenograft models that have been created by injecting human 
retinoblastoma tumour cells into either the anterior chamber or the subretinal space 
of the eyes of immunodeficient mice or rats (Chevez-Barrios et al., 2000). The first 
animal model of retinoblastoma was introduced by injecting human retinoblastoma 
cells (Y79) into immunocompromised mice by McFall et al., (1974). However, it 
was not an ideal model due to obvious anatomic difference between the adult flank 
and the eye (White et al., 1989). 
 
Chevez-Barrios et al., (2000) developed another animal model by injecting human 
retinoblastoma cell lines in mice. The WERI-Rb cell line and Y79 retinoblastoma 
cell line were used, where both derived from undifferentiated human retinoblastoma. 
These tumour cell lines were cultured and the tumour cells were injected 
intravitreally in mice. From the study, the former cell line produce more closely 
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resembled non-metastatic human retinoblastoma whereas the latter demonstrated 
specific tumour evolution similar to that seen in invasive and metastatic disease. 
 
Rabbit model of retinoblastoma has recently been established by (Kang & 
Grossniklaus, 2011) where the WERI-Rb cell line was injected in the cyclosporin-
induced immunodeficient rabbit. The tumour was detectable starting at week one 
post injection in all rabbit, then became vascularised starting at week five and 
continue to increase in size up to eight week. The advantage of using this rabbit 
model is their larger eye size which is similar to human infant’s eye that permits 
better visualization for clinical assessment, administration of tumour cells and 
intraocular drug delivery.  
 
The WERI-Rb cell line is one of two retinoblastoma cell line that has been 
established in 1974. (Mcfall et al., 1977) It shows similar morphology as compared 
to the earlier Y79 cell line in vitro. WERI-Rb cell line grew as a suspension of small 
round cells in grape-like clusters in 3 dimensions. Each exhibited growth of cells in 
rosettes, as well as unusual chain formations. The population-doubling times for 
WERI-Rb were 96 hour.   
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1.4 Tumour angiogenesis and vascular endothelial growth factor (VEGF)  
 
Angiogenesis, the recruitment of new blood vessels is an essential component in 
tumour growth and metastasis (Zetter, 1998). Angiogenesis enhances entry of 
tumour cells into the circulation by providing an increased density of immature, 
highly permeable blood vessels that have little basement membrane and fewer 
intercellular junctional complexes than normal mature vessels (Dvorak et al., 1995). 
Folkman et al., (1971) made initial efforts aimed to isolate a tumour angiogenesis 
factor from human and animal tumours. Subsequently, the angiogenic effects of 
various factors, including TGF-α TGFβ , TNF-α, and angiogenin were reported. 
Although these factors promoted angiogenesis in various bioassays, initial attempts 
to directly link them to tumour angiogenesis yielded largely negative results (Ferrara, 
2002). However, recent studies had demonstrated the expression of VEGF in 
tumours. In situ hybridization studies demonstrated that the VEGF mRNA is 
expressed in the vast majority of human tumours. Many tumour cell lines secrete 
VEGF in vitro suggesting that the possibility of this molecule may be a mediator of 
tumour angiogenesis (Ferrara, 2004). 
 
Vascular endothelial growth factor (VEGF) is an endothelial cell-specific mitogen in 
vitro and an angiogenic inducer in various in vivo models. Hypoxia has been shown 
to be a major inducer of VEGF gene transcription (Ferrara, 2004). The history of 
VEGF began in 1983 when Senger et al. discovered the partial purification from the  
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conditioned medium of a guinea-pig tumour cell line of a protein able to induce 
vascular leakage in the skin, which was termed “tumour vascular permeability 
factor” (VPF). VPF had been suggested to be a mediator of the high permeability of 
tumour blood vessels; unfortunately it was not isolated and sequenced. Hence, this 
factor remained molecularly unknown at that time. VEGF was formally identified in 
1989 by Ferrara & Henzel when they isolate a diffusible endothelial cell-specific 
mitogen from medium conditioned by bovine pituitary follicular cells. The role of 
VEGF in developmental angiogenesis is further emphasized when loss of a single 
VEGF allele results in defective vascularisation and early embryonic lethality 
(Ferrara, 2004). VEGF is currently established as a major regulator of physiological 
and pathological angiogenesis.  
 
1.4.1 Tumour angiogenesis in retinoblastoma 
 
Retinoblastoma is a well vascularised tumour that is dependent on its vascular 
supply (Burnier et al., 1990). Study by Kvanta et al., (1996) and Arean et.al., (2010) 
showed that VEGF is highly expressed in patients with retinoblastoma. Piña et al., 
(2009) found a heterogeneous vessel population in retinoblastoma containing both 
neovessels and mature vessels in advanced disease. Another study done by Rossler et 
al. (2004)  on 107 retinoblastomas collected between 1980 and 1990, demonstrated 
that vessel density in retinoblastoma correlate with local invasive growth and the 
presence of metastasis at the time of diagnosis. Therefore, angiogenesis seems to  
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play an important role for invasive growth in retinoblastoma both locally and 
systemically. Hence, anti-angiogenesis therapy may play an important (adjuvant) 
role in the regression of tumour growth and prevention of metastases of 
retinoblastoma. 
 
1.4.2 Anti vascular endothelial growth factor (antiVEGF) 
 
Various clinical trials regarding the intravitreal injection of anti-VEGF agents 
including ranibizumab, bevacizumab, pegaptanib, and aflibercept have shown 
excellent results in the treatment of angiogenic pathologies including choroidal 
neovascularisation, macular edema, proliferative diabetic retinopathy and 
neovascular glaucoma (Kimoto & Kubota, 2012). Bevacizumab and ranibizumab 
target all VEGF isoforms while pegaptanib specifically targets the 165 isoform of 
VEGF (Christoforidis et al., 2012). Ranibizumab contains a fragment of a humanized 
monoclonal antibody, is proven beneficial in the treatment of choroidal 
neovascularization secondary to age-related macular degeneration. Bevacizumab is a 
humanized recombinant monoclonal IgG antibody that has been approved as an 
adjuvant agent for the treatment of colorectal carcinoma and has also been 
increasingly used as an off-label therapy in the field of ophthalmology.  
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1.4.3 The role of antiVEGF as adjuvant therapy of tumour  
 
VEGF-blocking therapy appears very promising in the treatment of cancer as it is 
directed only against migrating and proliferating capillary endothelial cells at a site 
of angiogenesis (Hoeben et al., 2004). Combination therapy seems more effective, 
because both the endothelial cell and tumour cell compartments of a tumour are 
targeted and blocking angiogenesis may decrease the interstitial pressure in tumours, 
leading to a greater penetration of the cytotoxic drugs. 
 
 The era of antiangiogenic treatment for cancer began in 2004, with the approval of 
bevacizumab for the treatment of metastatic colorectal cancer. Lee et al., (2008) 
conducted a study on inhibitory effect of bevacizumab on the angiogenesis and 
growth of retinoblastoma. In this study, systemic administration of bevacizumab was 
injected into nude mice induced with retinoblastoma. There was 75% reduction in 
the growth of retinoblastoma without producing significant systemic toxicity. 
Another study done by Houston et al., (2011) on vascular targeting therapies with 
angiogenic inhibitors alone or in combination with chemotherapeutic agents have 
been shown to effectively control tumour burden in the knockout mouse model for 
retinoblastoma.  
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Based on the promising outcome from the previous studies, intravitreal 
administration of antiVEGF is potentially advantageous and might have the same 
inhibitory effect as the one given via systemic route. (Lee et al. 2008; Houston et al. 
2011). Ranibizumab is a monoclonal antibody fragment have a higher binding 
affinity for VEGF possibly has similar efficacy as bevacizumab as adjuvant therapy 
in tumour. To date, there was no study done on intravitreal antiVEGF therapy on 
retinoblastoma. Intravitreal ranibizumab injection may have possible advantageous 
effect as it directly targeting the source of lesion. It also confers less antigenicity and 
greater retinal penetration because of the smaller molecule size. Administration of 
intravitreal ranibizumab will reduce the VEGF load intraocularly. Therefore, reduce 
the inflammatory process, risk of new vessel formation and further reduce the 
aggressiveness and growth of retinoblastoma.  
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2.  STUDY OBJECTIVE 
 
2.2 General Objective 
To evaluate the efficacy and potential side effect of intravitreal ranibizumab  
injection as adjunctive therapy for retinoblastoma in rabbits 
 
2.3       Specific Objectives 
i. To determine the regression of tumour size after 0.5mg intravitreal  
          ranibizumab injection in rabbit  induced with retinoblastoma 
ii. To determine the potential side effect of 0.5mg intravitreal  
           ranibizumab  injection in rabbit induced with retinoblastoma 
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 3. MATERALS AND METHOD 
 
3.1 Research design 
Animal experimental study 
 
3.2 Population and setting time 
Six healthy New Zealand albino rabbits obtained from Animal Research and 
Study Centre (ARASC), Universiti Sains Malaysia, Health Campus, Kubang 
Kerian, Kelantan 
 
3.3       Ethical approval and financial support 
This study received approval from Animal Ethics Committee, Health 
Campus, Universiti Sains Malaysia on 30
th
 January 2013 with reference 
number USM/Animal Ethics Approval/2012/(81)(429) and was supported by 
short term grant (304/PPSP/61313066). 
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3 .4 Sampling method 
3.4.1   Sampling method 
Six New Zealand albino rabbit, weighing around 3kg, were recruited in this 
study. All rabbits were free from any ocular disease. They are kept, fed and 
cared in ARASC. The animals were divided into two group; Group A (treated 
group) and Group B (control group). 
 
3.4.2   Sample size 
The sample size was determined based on the two proportion formula using 
PS software version 3.0.  
i. Power of study (1-β) = 80% 
ii. Significant level (α) = 5% 
iii. Ratio between control group and the treated group (m) = 1 
iv. P0 = 0.95 (Lee et. al., 2008) 
v. P1 = 0.01 
vi. Detectable difference: 0.9 
i. Sample size calculated = 3 per group  
ii. Sample size of this study is 3 rabbits per group           
 
 
 24 
 
 
3.5 Selection criteria 
3.5.1 Inclusion criteria 
All rabbits that were successfully induced with retinoblastoma 
3.5.2 Exclusion criteria 
i. Evidence of early cachexia before commencing treatment 
ii. The presence of concomitant ocular infection. 
iii. The development of severe infection post intraocular injection, retinal 
detachment or vitreous haemorrhage. 
 
3.6 Definition of Terms 
3.6.1    Successful induction of tumour: 
i. Single tumour at least 1disc diameter size 
ii. Multiple tumour less than one disc diameter 
 
3.6.2    Regression of tumour 
Tumour regression pattern were initially described following radiotherapy 
(ERBT) and include: 
Type 0: no remnant (tumour completely disappears, leaving no retinal  
